http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고정화 효소를 사용한 시트르산 생성에 있어서 미량원소의 영향
임동준,최차용 한국화학공학회 1985 Korean Chemical Engineering Research(HWAHAK KONGHA Vol.23 No.1
고정화된 효소세포 Candida lipolytica MX9-11R3를 세포 자체를 칼시움 알지내이트 겔에 포괄시켜 만들었다. 이들 고정화된 효모세포를 사용하여 유동층 반응기 내에서 시트르산을 생산할때의 미량원소의 영향을 연구하였다. 배양액 조성 가운데 포도당 이외의 다른 성분들을 제거함으로써 세포증식을 정지시킬 수 있었다. 이 포도당 용액에 황산 제1철을 가하였을 때는 시트르산 수율의 감소를, 그리고 포도당용액의 황산 암모니움의 초기농도를 증가시켰을 때는 시트르산 생산수율의 향상을 가져왔다. 시트르산 생성을 위한 황산아연과 황산구리의 최적농도는 각각 5㎎/liter, 0.05㎎/liter였다. 황산망간이나 염화칼슘의 포도당용액에의 첨가는 시트르산 생산에 대해서 뚜렷한 효과가 없다. Immobilized yeast cells (Candida lipolytica MX9-11 R3) were prepared by entrapping the whole cells in calcium alginate gel. The effects of minor elements on citric acid production were studied using the immobilized yeast cells in a fluidized-bed batch reactor. One could more of less prevent the cell growth using glucose as the sole nutrient in the medium and thus removing other nutrients from the recipe for complex medium necessary for cell mass doubling. When ferrous sulfate was added into glucose solution, the yield of citric acid was decreased whereas increasing the initial concentration of ammonium sulfate in the glucose solution resulted in the enhancement of the citric acid yield. The optimal concentrations of zinc sulfate and cupric sulfate for citric acid production were found to be 5㎎/ℓ, 0.05㎎/ℓ respectively. Addition of either manganese sulfate or calcium chloride into the glucose solution had no appreciable effect on the citric acid production.
임동준 대한갑상선학회 2018 International Journal of Thyroidology Vol.11 No.2
Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality of life and therapeutic effectiveness, it is essential to cope with a variety of severity of skin-related toxicity induced by MTKI. Herein, we will discuss two representative cases of skin-related toxicities which were managed by discontinuation/ reduction of therapeutic doses of MTKI and were treated by proper medication in thyroid cancer patients with distant metastasis.